Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Scancell Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Scancell Holdings's earnings are forecast to decline at 13.4% per annum. Der Gewinn pro Aktie wird voraussichtlich sinken um 4.4% pro Jahr.

Wichtige Informationen

-13.4%

Wachstumsrate der Gewinne

-4.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.1%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Mar 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Oct 29

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Feb 10

Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Dec 28

Gewinn- und Umsatzwachstumsprognosen

AIM:SCLP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
4/30/2026	N/A	-15	-11	-13	2
4/30/2025	N/A	-14	-11	-11	3
4/30/2024	N/A	-15	-15	-15	3
10/31/2023	N/A	-10	-11	-11	N/A
7/31/2023	3	-11	-9	-9	N/A
4/30/2023	5	-12	-8	-8	N/A
1/31/2023	5	-13	-9	-9	N/A
10/31/2022	5	-13	-11	-10	N/A
7/31/2022	3	-9	-11	-10	N/A
4/30/2022	N/A	-5	-11	-10	N/A
1/31/2022	N/A	-6	-11	-10	N/A
10/31/2021	N/A	-8	-11	-9	N/A
7/31/2021	N/A	-12	-10	-8	N/A
4/30/2021	N/A	-15	-9	-8	N/A
1/31/2021	N/A	-11	-7	-7	N/A
10/31/2020	N/A	-7	-6	-5	N/A
7/31/2020	N/A	-6	-5	-5	N/A
4/30/2020	N/A	-6	-5	-5	N/A
1/31/2020	N/A	-5	-5	-5	N/A
10/31/2019	N/A	-5	-6	-6	N/A
7/31/2019	N/A	-5	-6	-6	N/A
4/30/2019	N/A	-6	-7	-7	N/A
1/31/2019	N/A	-6	-6	-6	N/A
10/31/2018	N/A	-5	-6	-6	N/A
7/31/2018	N/A	-5	-5	-5	N/A
4/30/2018	N/A	-4	-4	-4	N/A
1/31/2018	N/A	-4	-4	-4	N/A
10/31/2017	N/A	-4	-4	-4	N/A
7/31/2017	N/A	-4	N/A	-4	N/A
4/30/2017	N/A	-4	N/A	-4	N/A
1/31/2017	N/A	-3	N/A	-3	N/A
10/31/2016	N/A	-3	N/A	-3	N/A
7/31/2016	N/A	-3	N/A	-3	N/A
4/30/2016	N/A	-3	N/A	-2	N/A
1/31/2016	N/A	-2	N/A	-2	N/A
10/31/2015	N/A	-2	N/A	-3	N/A
7/31/2015	N/A	-2	N/A	-3	N/A
4/30/2015	N/A	-2	N/A	-3	N/A
1/31/2015	N/A	-2	N/A	-2	N/A
10/31/2014	N/A	-2	N/A	-2	N/A
7/31/2014	N/A	-2	N/A	-2	N/A
4/30/2014	N/A	-2	N/A	-2	N/A
1/31/2014	N/A	-2	N/A	-2	N/A
10/31/2013	N/A	-2	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SCLP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SCLP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SCLP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SCLP schneller wachsen werden als der Markt von UK.

Hohe Wachstumseinnahmen: SCLP wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SCLP in 3 Jahren voraussichtlich hoch sein wird

Scancell Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 12% to UK£0.23

Price target increased by 8.6% to UK£0.27

Recent updates

New minor risk - Market cap size

Scancell Holdings plc Appoints Sath Nirmalananthan to the Board

Scancell Holdings plc Directorate and Executive Changes Changes

New minor risk - Share price stability

Scancell Holdings plc to Report First Half, 2024 Results on Jan 30, 2024

Scancell Holdings plc Announces Update on SCOPE Trial

Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £11.897217 million.

Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £12.672161 million.

Price target decreased by 12% to UK£0.23

Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £8.08 million.

New major risk - Negative shareholders equity

Scancell Holdings plc, Annual General Meeting, Nov 29, 2023

Scancell Holdings plc to Report Q4, 2023 Results on Oct 12, 2023

Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free

Scancell Holdings plc Announces Positive Data from the First Stage in its Phase 2 Scope Trial with SCIB1 Cancer Vaccine Delivered by Needle Free Injection for Advanced Melanoma

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets SCIB1/iSCIB-1+ and Modi-1

Scancell Holdings plc Announces Appointment of Dr Mandeep Sehmi as Head of Business Development

Scancell Appoints Sath Nirmalananthan as CFO

New minor risk - Financial data availability

New minor risk - Market cap size

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1

Scancell Holdings plc Announces Positive Response in Covidity Trial

Scancell Holdings plc Announces Executive Changes

Price target increased by 8.6% to UK£0.27

Scancell Holdings plc to Report First Half, 2023 Results on Jan 25, 2023

Less than half of directors are independent

Scancell Holdings plc Announces First Patient Dosed in Expansion Phase of Modify

Scancell Holdings plc, Annual General Meeting, Nov 21, 2022

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Scancell Holdings plc Announces Board Changes

Scancell Holdings plc Announces First Patient Dosed in Cohort 2 of the ModiFY Phase 1 Clinical Trial

Scancell Holdings plc to Produce TCB Antibodies

Scancell Holdings plc Announces an Update to the Phase 2 Scope Clinical Trial

Scancell Holdings plc Announces the Enrolment and Treatment of the First Patient in Its Multicentre Modi-1 Clinical Trial (Modify) At Imperial College London, Hammersmith Hospital

Less than half of directors are independent

Scancell Holdings plc Announces Modi-1 Phase 1/2 Trial Open for Recruitment

Scancell Holdings plc Announces Update on Covidity Clinical Trial

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Scancell Holdings plc Announcedsfurther Progress of the Phase 1 Covidity Clinical Trial Being Conducted At the University of Cape Town (UCT) Lung Institute in South Africa

Scancell Holdings plc Announces the UK's Medicines and Healthcare Products Regulatory Authority Approves the Clinical Trial Application to Initiate the First-in-Human Phase I/II Clinical Study of Modi-1

CEO & Director Clifford Holloway has left the company

Scancell Holdings plc Announces COVIDITY Phase 1 Clinical Trial Planned in South Africa and UK for Novel Bivalent COVID-19 Vaccine

New 90-day high: UK£0.21

Scancell Holdings plc Announces an Update on its SCIB2 Clinical Development Partnership with Cancer Research UK

Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Scancell Holdings plc Appoints Gillies O'Bryan-Tear as Chief Medical Officer and Robert Miller as Medical Director

Scancell Holdings plc to Report Fiscal Year 2020 Results on Oct 16, 2020

Cobra Biologics and Scancell Holdings plc Announces Collaboration to Manufacture COVID-19 Vaccine

Scancell Holdings plc announced that it expects to receive £1.3 million in funding from Cherwell Capital plc, Oxford Technology Management Limited, Oxford Capital Partners LLP, Seneca Partners Limited, Octopus Investments Limited

Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £9.007417 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken